01—Abstract
Summary
Summary of the 10-Q filed May 5, 2025. Cited figures are marked; the original filing is the authoritative source.
Pfizer Inc. reported total revenues of $13.7 billiona for the first quarter ended March 30, 2025, a decrease of 8% compared to $14.9 billion in the prior year period.
This decline was primarily attributed to a significant drop in Paxlovid sales, which were impacted by lower COVID-19 infections and reduced government purchases, as well as the non-recurrence of a favorable revenue adjustment recognized in the prior year. Despite the overall revenue decrease, operational improvements and growth in key therapeutic areas like the Vyndaqel family, Padcev, and Lorbrena provided some offset. Net income attributable to Pfizer Inc. common shareholders was $2.97 billionb, or $0.52 per diluted share, compared to $3.12 billion, or $0.55 per diluted share, in the first quarter of 2024.
The decrease in profitability was influenced by lower revenues, increased restructuring charges, and higher intangible asset impairment charges. However, the company is actively managing its cost base through ongoing productivity initiatives and cost realignment programs, which are expected to yield significant savings. Pfizer also completed the sale of its remaining investment in Haleon, generating $6.3 billionc in proceeds to support its capital allocation priorities.
02—Key points
Key Highlights
- Total revenues decreased by 8% to $13.7 billion in Q1 2025, primarily due to a substantial decline in Paxlovid sales.
- Net income attributable to Pfizer Inc. common shareholders was $2.97 billion, down from $3.12 billion in Q1 2024.
- Diluted EPS was $0.52, a decrease from $0.55 in the prior year quarter.
- The company incurred $678 million in restructuring charges and acquisition-related costs in Q1 2025, a significant increase from $102 million in Q1 2024.
- Pfizer sold its remaining investment in Haleon for $6.3 billion during the quarter.
- Key growth drivers included the Vyndaqel family (up 33% operationally), Padcev (up 25% operationally), and Lorbrena (up 39% operationally).
- The company continues to implement cost realignment and manufacturing optimization programs, aiming for substantial cost savings.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ1 FY2025filed May 5, 2025Financial Statements
Q1 FY2025 against Q1 FY2024
| Line item | Q1 FY2025Q1 FY2024 | Change |
|---|---|---|
| Revenue | $13.71B$14.88B | −7.8% |
| Cost of Revenue | $2.85B$3.38B | −15.8% |
| Gross Profit | $10.87B$11.50B | −5.5% |
| SG&A Expenses | $3.03B$3.50B | −13.3% |
| Interest Expense | $654.00M$790.00M | −17.2% |
| Net Income | $2.97B$3.12B | −4.8% |
| EPS (Basic) | $0.52$0.55 | −5.5% |
| EPS (Diluted) | $0.52$0.55 | −5.5% |
| Shares Outstanding (Basic) | 5.67B5.66B | +0.3% |
| Shares Outstanding (Diluted) | 5.71B5.70B | +0.2% |
05—Questions
Frequently Asked Questions
What were the primary drivers of the revenue decline in the first quarter?
The primary driver of the revenue decline was a significant 75% decrease in Paxlovid sales. This was due to lower COVID-19 infections, reduced government purchases, and the non-recurrence of a favorable revenue adjustment that was recognized in the first quarter of 2024.
How is Pfizer managing costs and expenses?
Pfizer is actively managing costs through its 'Realigning Our Cost Base Program' and a 'Manufacturing Optimization Program.' These initiatives aim to realign costs with long-term revenue expectations and reduce the cost of goods sold, with a focus on digital enablement, AI, and business process simplification. These programs are expected to generate significant cost savings.
What is the impact of the Inflation Reduction Act (IRA) on Pfizer's business?
The IRA continues to impact Pfizer, particularly through the Medicare Part D Redesign, which is expected to have a net unfavorable impact of approximately $1 billion on revenue in 2025 due to changes in manufacturer discounts and benefit design. Eliquis, Ibrance, and Xtandi have also been identified for Medicare drug price negotiation, with potential price reductions impacting future revenues.
What is the significance of the sale of the Haleon investment?
Pfizer sold its remaining stake in Haleon for $6.3 billion during the first quarter of 2025. This divestment provides significant capital that the company intends to use to support its capital allocation priorities, which include dividends, reinvestment in the business, and share repurchases.
06—Continue